<p>Mineralys Therapeutics, Inc. (NASDAQ:MLYS - 获取免费报告) 的股价在周四的午盘交易中达到了新的 52 周高点。该公司的股价最高达到 39.50 美元，最后交易价格为 39.49 美元，成交量为 337173 股。该股票此前收盘价为 37.29 美元。</p>
<p>获取 <strong>Mineralys Therapeutics</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<ul>
<li>关于 Mineralys 的情人节 IPO 有很多值得期待的地方</li>
</ul>
<p>一些股票研究分析师最近对 MLYS 股票发布了报告。HC Wainwright 在 9 月 8 日的报告中重申了 “买入” 评级，并将 Mineralys Therapeutics 的目标价设定为 42.00 美元。高盛集团在 9 月 9 日的报告中将 Mineralys Therapeutics 的目标价从 32.00 美元上调至 52.00 美元，并给予该股票 “买入” 评级。华尔街 Zen 在 8 月 22 日的报告中将 Mineralys Therapeutics 的评级从 “卖出” 上调至 “持有”。富国银行在 9 月 11 日的研究报告中将 Mineralys Therapeutics 的目标价从 26.00 美元上调至 50.00 美元，并给予该公司 “增持” 评级。最后，美国银行在 8 月 28 日的研究报告中将 Mineralys Therapeutics 的目标价从 38.00 美元上调至 43.00 美元，并给予该公司 “买入” 评级。五位投资分析师对该股票给予了 “买入” 评级，一位分析师给予了 “持有” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 43.50 美元。</p>
<p><strong>查看我们对 MLYS 的最新分析</strong></p>
<h2>Mineralys Therapeutics 股票上涨 7.8%</h2>
<p>该公司的市值为 26.7 亿美元，市盈率为-11.26，贝塔值为-0.29。该公司的 50 日移动平均价格为 19.30 美元，200 日移动平均价格为 16.03 美元。</p>
<p>Mineralys Therapeutics (NASDAQ:MLYS - 获取免费报告) 最近在 8 月 12 日发布了季度财报。该公司报告每股收益为 (-0.66) 美元，超出市场共识预期的 (-0.78) 美元，超出幅度为 0.12 美元。平均而言，股票分析师预计 Mineralys Therapeutics, Inc.在当前财政年度的每股收益为-4.23 美元。</p>
<h2>内部人士下注</h2>
<p>在其他消息中，首席财务官 Adam Scott Levy 在 7 月 30 日的交易中出售了 59,925 股该股票。该股票以平均价格 14.76 美元出售，总价值为 884,493.00 美元。出售完成后，首席财务官直接持有 132,934 股公司股票，价值约为 1,962,105.84 美元。这代表其持股比例减少了 31.07%。该交易已在证券交易委员会的法律文件中披露，可以通过此链接访问。此外，首席执行官 Jon Congleton 在 7 月 11 日的交易中出售了 15,884 股该股票。该股票以平均价格 14.51 美元出售，总价值为 230,476.84 美元。出售完成后，首席执行官直接持有 846,405 股公司股票，价值为 12,281,336.55 美元。该交易使其持股比例减少了 1.84%。该交易的披露信息可以在这里找到。在过去三个月中，内部人士出售了 134,418 股公司股票，价值为 2,185,474 美元。25.56% 的股票由内部人士持有。</p>
<h2>机构投资者对 Mineralys Therapeutics 的看法</h2>
<p>几家对冲基金最近调整了对 MLYS 的持股。北方信托公司在第四季度将其在 Mineralys Therapeutics 的持股提高了 0.7%。北方信托公司目前拥有 246,113 股公司股票，价值 3,030,000 美元，在此期间又购买了 1,688 股。法国巴黎银行金融市场在第四季度获得了 Mineralys Therapeutics 的新股份，价值 48,000 美元。美国银行在第四季度将其在 Mineralys Therapeutics 的持股提高了 12.0%。美国银行目前拥有 107,703 股公司股票，价值 1,326,000 美元，在此期间又购买了 11,549 股。德意志银行在第四季度将其在 Mineralys Therapeutics 的持股提高了 62.3%。德意志银行目前拥有 26,732 股公司股票，价值 329,000 美元，在此期间又购买了 10,264 股。最后，Millennium Management LLC 在第四季度将其在 Mineralys Therapeutics 的持股提高了 1,015.8%。Millennium Management LLC 目前拥有 1,101,674 股公司股票，价值 13,562,000 美元，在此期间又购买了 1,002,941 股。84.46% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Mineralys Therapeutics</h2>
<p>(获取免费报告)</p>
<p>Mineralys Therapeutics, Inc.是一家临床阶段的生物制药公司，开发用于治疗高血压和慢性肾病的疗法。其临床阶段的产品候选药物是 lorundrostat，一种专有的口服给药、高选择性的醛固酮合成酶抑制剂，用于治疗受异常升高的醛固酮影响的心肾疾病。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 Mineralys Therapeutics</li>
<li>成长股：它们是什么，示例及如何投资</li>
<li>美联储降息：现在 S&amp;P 500 和股市该怎么办？</li>
<li>投资的股票类型各不相同</li>
<li>Bloom Energy 因 AI 电力需求和分析师升级而蓬勃发展</li>
<li>宠物是大生意：4 只值得投资的宠物股票</li>
<li>新催化剂为英特尔股票带来积极压力</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Mineralys Therapeutics 吗？</h2>
<p>在考虑 Mineralys Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Mineralys Therapeutics 并不在名单上。</p>
<p>虽然 Mineralys Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MLYS

<p>Mineralys Therapeutics（纳斯达克代码：MLYS）达到了新的 52 周高点 39.50 美元，收盘价为 39.49 美元，交易量为 337,173 股。分析师们给予了积极的评级，HC Wainwright 维持 “买入” 评级，目标价为 42.00 美元，而高盛将其目标价从 32.00 美元上调至 52.00 美元。该公司的市值为 26.7 亿美元，报告每股收益为（0.66 美元），超出预期。内部人士最近出售了股份，机构投资者持有该股票的 84.46%</p>

<p>Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $39.50 and last traded at $39.49, with a volume of 337173 shares. The stock had previously closed at $37.29.</p>
<div class="lb-trans"><p>Mineralys Therapeutics, Inc. (NASDAQ:MLYS - 获取免费报告) 的股价在周四的午盘交易中达到了新的 52 周高点。该公司的股价最高达到 39.50 美元，最后交易价格为 39.49 美元，成交量为 337173 股。该股票此前收盘价为 37.29 美元。</p>
</div><p>Get <strong>Mineralys Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Mineralys Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>There's a Lot to Love About Mineralys' Valentine's Day IPO</li>
</ul>
<div class="lb-trans"><ul>
<li>关于 Mineralys 的情人节 IPO 有很多值得期待的地方</li>
</ul>
</div><p>A number of equities research analysts have recently issued reports on MLYS shares. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $42.00 target price on shares of Mineralys Therapeutics in a report on Monday, September 8th. The Goldman Sachs Group upped their target price on shares of Mineralys Therapeutics from $32.00 to $52.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, September 9th. Wall Street Zen raised shares of Mineralys Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Friday, August 22nd. Wells Fargo &amp; Company boosted their price target on shares of Mineralys Therapeutics from $26.00 to $50.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, September 11th. Finally, Bank of America upped their target price on shares of Mineralys Therapeutics from $38.00 to $43.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, August 28th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $43.50.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对 MLYS 股票发布了报告。HC Wainwright 在 9 月 8 日的报告中重申了 “买入” 评级，并将 Mineralys Therapeutics 的目标价设定为 42.00 美元。高盛集团在 9 月 9 日的报告中将 Mineralys Therapeutics 的目标价从 32.00 美元上调至 52.00 美元，并给予该股票 “买入” 评级。华尔街 Zen 在 8 月 22 日的报告中将 Mineralys Therapeutics 的评级从 “卖出” 上调至 “持有”。富国银行在 9 月 11 日的研究报告中将 Mineralys Therapeutics 的目标价从 26.00 美元上调至 50.00 美元，并给予该公司 “增持” 评级。最后，美国银行在 8 月 28 日的研究报告中将 Mineralys Therapeutics 的目标价从 38.00 美元上调至 43.00 美元，并给予该公司 “买入” 评级。五位投资分析师对该股票给予了 “买入” 评级，一位分析师给予了 “持有” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 43.50 美元。</p>
</div><p><strong>View Our Latest Analysis on MLYS</strong></p>
<div class="lb-trans"><p><strong>查看我们对 MLYS 的最新分析</strong></p>
</div><h2>Mineralys Therapeutics Stock Up 7.8%</h2>
<div class="lb-trans"><h2>Mineralys Therapeutics 股票上涨 7.8%</h2>
</div><p>The firm has a market capitalization of $2.67 billion, a price-to-earnings ratio of -11.26 and a beta of -0.29. The company has a fifty day moving average price of $19.30 and a two-hundred day moving average price of $16.03.</p>
<div class="lb-trans"><p>该公司的市值为 26.7 亿美元，市盈率为-11.26，贝塔值为-0.29。该公司的 50 日移动平均价格为 19.30 美元，200 日移动平均价格为 16.03 美元。</p>
</div><p>Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.12. On average, equities analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Mineralys Therapeutics (NASDAQ:MLYS - 获取免费报告) 最近在 8 月 12 日发布了季度财报。该公司报告每股收益为 (-0.66) 美元，超出市场共识预期的 (-0.78) 美元，超出幅度为 0.12 美元。平均而言，股票分析师预计 Mineralys Therapeutics, Inc.在当前财政年度的每股收益为-4.23 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CFO Adam Scott Levy sold 59,925 shares of the stock in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $14.76, for a total value of $884,493.00. Following the completion of the sale, the chief financial officer directly owned 132,934 shares of the company's stock, valued at approximately $1,962,105.84. This represents a 31.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jon Congleton sold 15,884 shares of the stock in a transaction that occurred on Friday, July 11th. The shares were sold at an average price of $14.51, for a total value of $230,476.84. Following the completion of the sale, the chief executive officer directly owned 846,405 shares of the company's stock, valued at $12,281,336.55. The trade was a 1.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 134,418 shares of company stock valued at $2,185,474. 25.56% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席财务官 Adam Scott Levy 在 7 月 30 日的交易中出售了 59,925 股该股票。该股票以平均价格 14.76 美元出售，总价值为 884,493.00 美元。出售完成后，首席财务官直接持有 132,934 股公司股票，价值约为 1,962,105.84 美元。这代表其持股比例减少了 31.07%。该交易已在证券交易委员会的法律文件中披露，可以通过此链接访问。此外，首席执行官 Jon Congleton 在 7 月 11 日的交易中出售了 15,884 股该股票。该股票以平均价格 14.51 美元出售，总价值为 230,476.84 美元。出售完成后，首席执行官直接持有 846,405 股公司股票，价值为 12,281,336.55 美元。该交易使其持股比例减少了 1.84%。该交易的披露信息可以在这里找到。在过去三个月中，内部人士出售了 134,418 股公司股票，价值为 2,185,474 美元。25.56% 的股票由内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Mineralys Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Mineralys Therapeutics 的看法</h2>
</div><p>Several hedge funds have recently modified their holdings of MLYS. Northern Trust Corp lifted its holdings in shares of Mineralys Therapeutics by 0.7% during the fourth quarter. Northern Trust Corp now owns 246,113 shares of the company's stock worth $3,030,000 after purchasing an additional 1,688 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Mineralys Therapeutics during the fourth quarter worth $48,000. Bank of America Corp DE lifted its holdings in shares of Mineralys Therapeutics by 12.0% during the fourth quarter. Bank of America Corp DE now owns 107,703 shares of the company's stock worth $1,326,000 after purchasing an additional 11,549 shares during the period. Deutsche Bank AG lifted its holdings in shares of Mineralys Therapeutics by 62.3% during the fourth quarter. Deutsche Bank AG now owns 26,732 shares of the company's stock worth $329,000 after purchasing an additional 10,264 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Mineralys Therapeutics by 1,015.8% during the fourth quarter. Millennium Management LLC now owns 1,101,674 shares of the company's stock worth $13,562,000 after purchasing an additional 1,002,941 shares during the period. 84.46% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对 MLYS 的持股。北方信托公司在第四季度将其在 Mineralys Therapeutics 的持股提高了 0.7%。北方信托公司目前拥有 246,113 股公司股票，价值 3,030,000 美元，在此期间又购买了 1,688 股。法国巴黎银行金融市场在第四季度获得了 Mineralys Therapeutics 的新股份，价值 48,000 美元。美国银行在第四季度将其在 Mineralys Therapeutics 的持股提高了 12.0%。美国银行目前拥有 107,703 股公司股票，价值 1,326,000 美元，在此期间又购买了 11,549 股。德意志银行在第四季度将其在 Mineralys Therapeutics 的持股提高了 62.3%。德意志银行目前拥有 26,732 股公司股票，价值 329,000 美元，在此期间又购买了 10,264 股。最后，Millennium Management LLC 在第四季度将其在 Mineralys Therapeutics 的持股提高了 1,015.8%。Millennium Management LLC 目前拥有 1,101,674 股公司股票，价值 13,562,000 美元，在此期间又购买了 1,002,941 股。84.46% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Mineralys Therapeutics</h2>
<div class="lb-trans"><h2>关于 Mineralys Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.</p>
<div class="lb-trans"><p>Mineralys Therapeutics, Inc.是一家临床阶段的生物制药公司，开发用于治疗高血压和慢性肾病的疗法。其临床阶段的产品候选药物是 lorundrostat，一种专有的口服给药、高选择性的醛固酮合成酶抑制剂，用于治疗受异常升高的醛固酮影响的心肾疾病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Mineralys Therapeutics</li>
<li>Growth Stocks: What They Are, Examples and How to Invest</li>
<li>The Fed Cut Rates: What Now for the S&amp;P 500 and Equity Markets?</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Bloom Energy Booms on AI Power Demand and Analyst Upgrades</li>
<li>Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio</li>
<li>New Catalysts Build Positive Pressure on Intel Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Mineralys Therapeutics</li>
<li>成长股：它们是什么，示例及如何投资</li>
<li>美联储降息：现在 S&amp;P 500 和股市该怎么办？</li>
<li>投资的股票类型各不相同</li>
<li>Bloom Energy 因 AI 电力需求和分析师升级而蓬勃发展</li>
<li>宠物是大生意：4 只值得投资的宠物股票</li>
<li>新催化剂为英特尔股票带来积极压力</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Mineralys Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Mineralys Therapeutics 吗？</h2>
</div><p>Before you consider Mineralys Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Mineralys Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Mineralys Therapeutics 并不在名单上。</p>
</div><p>While Mineralys Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Mineralys Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Mineralys Therapeutics（NASDAQ:MLYS）达到新的一年高点 - 是否值得购买？